Matthew Venezia
Stock Analyst at Alliance Global Partners
(3.87)
# 1,605
Out of 4,460 analysts
12
Total ratings
36.4%
Success rate
39.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Venezia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTHI NeOnc Technologies Holdings | Initiated Coverage: Buy | $13 | $4.48 | +190.18% | 1 | May 19, 2026 | |
| CAPR Capricor Therapeutics | Reiterated: Buy | $51 | $24.08 | +111.79% | 6 | May 14, 2026 | |
| TSX: APS Aptose Biosciences Inc. | Downgraded: Hold | $17.74 → $2.41 | $2.14 | +12.62% | 2 | Nov 24, 2025 | |
| PLUR Pluri | Initiated Coverage: Buy | $12 | $2.09 | n/a | 1 | Jun 2, 2025 | |
| CBUS Cibus | Reiterated: Buy | $24 | $1.37 | n/a | 2 | May 9, 2025 |
NeOnc Technologies Holdings
May 19, 2026
Initiated Coverage: Buy
Price Target: $13
Current: $4.48
Upside: +190.18%
Capricor Therapeutics
May 14, 2026
Reiterated: Buy
Price Target: $51
Current: $24.08
Upside: +111.79%
Aptose Biosciences Inc.
Nov 24, 2025
Downgraded: Hold
Price Target: $17.74 → $2.41
Current: $2.14
Upside: +12.62%
Pluri
Jun 2, 2025
Initiated Coverage: Buy
Price Target: $12
Current: $2.09
Upside: n/a
Cibus
May 9, 2025
Reiterated: Buy
Price Target: $24
Current: $1.37
Upside: n/a